Cancer researchers have discovered surprising new functions for a protein called MYC, a powerful oncogene that is estimated to drive the development of almost half a million new cancer cases in the US every year. The study shows that MYC affects the efficiency and quality of protein production in lymphoma cells, fueling their rapid growth and altering their susceptibility to immunotherapy.